Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, P.O. Box 4959 Nydalen, 0424 Oslo, Norway.
Department of Physics, University of Oslo, Problemveien 7, 0315 Oslo, Norway.
Molecules. 2022 Aug 25;27(17):5429. doi: 10.3390/molecules27175429.
A search in PubMed revealed that 72 radionuclides have been considered for molecular or functional targeted radionuclide therapy. As radionuclide therapies increase in number and variations, it is important to understand the role of the radionuclide and the various characteristics that can render it either useful or useless. This review focuses on the physical characteristics of radionuclides that are relevant for radionuclide therapy, such as linear energy transfer, relative biological effectiveness, range, half-life, imaging properties, and radiation protection considerations. All these properties vary considerably between radionuclides and can be optimised for specific targets. Properties that are advantageous for some applications can sometimes be drawbacks for others; for instance, radionuclides that enable easy imaging can introduce more radiation protection concerns than others. Similarly, a long radiation range is beneficial in targets with heterogeneous uptake, but it also increases the radiation dose to tissues surrounding the target, and, hence, a shorter range is likely more beneficial with homogeneous uptake. While one cannot select a collection of characteristics as each radionuclide comes with an unchangeable set, all the 72 radionuclides investigated for therapy-and many more that have not yet been investigated-provide numerous sets to choose between.
在 PubMed 上进行检索后发现,已有 72 种放射性核素被认为可用于分子或功能靶向放射性核素治疗。随着放射性核素治疗的数量和种类不断增加,了解放射性核素的作用以及使其变得有用或无用的各种特性非常重要。本文重点介绍放射性核素在放射性核素治疗方面的物理特性,例如线性能量传递、相对生物效应、射程、半衰期、成像特性和辐射防护考虑。这些特性在放射性核素之间差异很大,可以针对特定的靶点进行优化。某些应用中具有优势的特性有时可能成为其他应用的缺点;例如,易于成像的放射性核素比其他放射性核素引入更多的辐射防护问题。同样,在摄取不均匀的靶标中,较长的射程是有益的,但它也会增加靶标周围组织的辐射剂量,因此,在摄取均匀的情况下,较短的射程可能更有益。虽然不能选择一系列特性,因为每个放射性核素都具有不可改变的特性集,但治疗中研究过的 72 种放射性核素——以及许多尚未研究过的放射性核素——都提供了许多可供选择的特性集。